The potential effects of introducing microneedle patch vaccines into routine vaccine supply chains.
Benin
Costs and Cost Analysis
Drug Delivery Systems
Humans
Immunization Programs
India
Influenza Vaccines
/ administration & dosage
Microinjections
Mozambique
Refrigeration
Rotavirus Vaccines
/ administration & dosage
Tetanus Toxoid
/ administration & dosage
Transdermal Patch
Vaccination
/ methods
Vaccines
/ administration & dosage
Delivery
Logistics
Microneedle patch
Supply chain
Journal
Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899
Informations de publication
Date de publication:
21 01 2019
21 01 2019
Historique:
received:
07
08
2018
revised:
21
11
2018
accepted:
04
12
2018
pubmed:
24
12
2018
medline:
20
2
2020
entrez:
23
12
2018
Statut:
ppublish
Résumé
Microneedle patch (MNP) technology is designed to simplify the process of vaccine administration; however, depending on its characteristics, MNP technology may provide additional benefits beyond the point-of-use, particularly for vaccine supply chains. Using the HERMES modeling software, we examined replacing four routine vaccines - Measles-containing vaccine (MCV), Tetanus toxoid (TT), Rotavirus (Rota) and Pentavalent (Penta) - with MNP versions in the routine vaccine supply chains of Benin, Bihar (India), and Mozambique. Replacing MCV with an MNP (5 cm An MNP for MCV, TT, Rota, or Penta would need to have a smaller or equal volume-per-dose than existing vaccine formulations and be able to be stored outside the cold chain for a continuous period of at least two months to provide additional benefits to all three supply chains under modeled conditions.
Sections du résumé
BACKGROUND
Microneedle patch (MNP) technology is designed to simplify the process of vaccine administration; however, depending on its characteristics, MNP technology may provide additional benefits beyond the point-of-use, particularly for vaccine supply chains.
METHODS
Using the HERMES modeling software, we examined replacing four routine vaccines - Measles-containing vaccine (MCV), Tetanus toxoid (TT), Rotavirus (Rota) and Pentavalent (Penta) - with MNP versions in the routine vaccine supply chains of Benin, Bihar (India), and Mozambique.
RESULTS
Replacing MCV with an MNP (5 cm
CONCLUSIONS
An MNP for MCV, TT, Rota, or Penta would need to have a smaller or equal volume-per-dose than existing vaccine formulations and be able to be stored outside the cold chain for a continuous period of at least two months to provide additional benefits to all three supply chains under modeled conditions.
Identifiants
pubmed: 30578088
pii: S0264-410X(18)31653-0
doi: 10.1016/j.vaccine.2018.12.008
pmc: PMC6559242
mid: NIHMS1029731
pii:
doi:
Substances chimiques
Influenza Vaccines
0
Rotavirus Vaccines
0
Tetanus Toxoid
0
Vaccines
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
645-651Subventions
Organisme : AHRQ HHS
ID : R01 HS023317
Pays : United States
Organisme : NIGMS NIH HHS
ID : U24 GM110707
Pays : United States
Organisme : NICHD NIH HHS
ID : U54 HD070725
Pays : United States
Informations de copyright
Copyright © 2018. Published by Elsevier Ltd.
Références
Vaccine. 2015 Sep 8;33(37):4712-8
pubmed: 25770786
Vaccine. 2014 Jul 7;32(32):4097-103
pubmed: 24814550
Vaccine. 2017 May 25;35(23):3135-3142
pubmed: 28455169
PLoS One. 2016 Dec 22;11(12):e0169030
pubmed: 28006012
Vaccine. 2013 Jul 25;31(34):3396-402
pubmed: 23174199
Vaccine. 2016 Jul 25;34(34):4062-7
pubmed: 27340098
Vaccine. 2015 Aug 14;33(34):4161-4
pubmed: 25896383
Drugs R D. 2016 Dec;16(4):327-338
pubmed: 27696306
Vaccine. 2012 Aug 17;30(38):5637-43
pubmed: 22789507
Vaccine. 2017 Apr 19;35(17):2217-2223
pubmed: 27670076
Vaccine. 2013 Jul 25;31(34):3403-9
pubmed: 23044406
Vaccine. 2017 Apr 19;35(17):2162-2166
pubmed: 28364925
J Control Release. 2016 Oct 28;240:135-141
pubmed: 26603347
J Control Release. 2016 Aug 28;236:47-56
pubmed: 27327766
Annu Rev Chem Biomol Eng. 2017 Jun 7;8:177-200
pubmed: 28375775
Vaccine. 2016 Sep 22;34(41):4998-5004
pubmed: 27576077
Lancet. 2007 Apr 14;369(9569):1277-1285
pubmed: 17434403
Vaccine. 2014 May 1;32(21):2518-9
pubmed: 24582633
Biomaterials. 2017 Jun;128:1-7
pubmed: 28285193
Lancet. 2017 Aug 12;390(10095):649-658
pubmed: 28666680
Health Aff (Millwood). 2011 Jun;30(6):1113-21
pubmed: 21653965